Advertisement
News
Subscribe to MDT Magazine News

Vystar® Corporation Secures a $3M Credit Facility to Fund Growth

March 15, 2011 5:32 am | by Bio-Medicine.Org | Comments

ATLANTA, March 15, 2011 /- Vystar® Corporation (OTC Bulletin Board: VYST ), the creator of Vytex® Natural Rubber Latex (NRL), a patented, all-natural raw material that significantly reduces antigenic proteins found in natural rubber latex, has secured $3 million in debt...

TOPICS:

NAFE Names Lilly to Top 50 Companies for Executive Women

March 15, 2011 5:32 am | by Bio-Medicine.Org | Comments

INDIANAPOLIS, March 15, 2011 /- Eli Lilly and Company (NYSE: LLY ) has been named to the 2011 NAFE Top 50 Companies for Executive Women by the National Association for Female Executives (NAFE).  The list recognizes organizations whose policies and practices encourage women's...

TOPICS:

iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061

March 15, 2011 5:32 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 15, 2011 /- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in...

TOPICS:
Advertisement

iTherX Appoints Stefan Zeuzem, M.D., as Chair of Scientific and Clinical Advisory Board

March 15, 2011 5:32 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 15, 2011 /- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that Stefan Zeuzem, M.D., has joined the company as Chair of the Scientific and Clinical Advisory Board.  Dr. Zeuzem will...

TOPICS:

LABS, Inc. Announces Alliance with Ambry Genetics to Expand Testing Solutions for the Reproductive Health Industry

March 15, 2011 5:32 am | by Bio-Medicine.Org | Comments

CENTENNIAL, Colo. and ALISO VIEJO, Calif., March 15, 2011 /- LABS, Inc., the recognized leader in microbiology, infectious disease screening, cell/molecular biology and immunological testing for the transplant and biomedical sciences communities, today announced an agreement with Ambry...

TOPICS:

Nottingham University Hospital is First U.K. User of Elekta's Electronic Medical Record Workspace for Image Guided Radiation Therapy

March 15, 2011 5:32 am | by Bio-Medicine.Org | Comments

NOTTINGHAM, England, March 15, 2011 /- Delivering Image Guided Radiation Therapy (IGRT) effectively and safely involves careful coordination of sophisticated systems, such as the therapy machine and its imaging subsystems, as well as the electronic medical record (EMR) used to schedule...

TOPICS:

Oconee Medical Center is Winner of Siemens 'Who Inspires You?' Video Contest

March 15, 2011 5:32 am | by Bio-Medicine.Org | Comments

LAS VEGAS, March 15, 2011 /- Oconee Medical Center in Seneca, S.C., is the winner of Siemens "Who Inspires You?" video contest and the recipient of a new MAMMOMAT® Inspiration, Siemens next generation full-field digital mammography system. (Photo:...

TOPICS:

Repligen imaging agent meets goal in study review

March 15, 2011 4:45 am | by The Associated Press | Comments

Repligen Corp. said that its imaging agent RG1068 met its goals in a late stage clinical trial, as it allowed radiologists to accurately scan the pancreas of their patients without producing many more false positives.The results, disclosed Monday, come from a new analysis of the trial. Repligen...

Advertisement

510(k) Implementation: Discussion of an On-line Repository of Medical Device Labeling, and of Making Device Photographs Available in a Public Database Without Disclosing Propr...

March 15, 2011 4:37 am | by U.S. Food & Drug Administration | Comments

CDRH is exploring the development of a searchable medical device labeling repository that would be accessible by the public and provide useful product information to patients and health care practitioners. This might be similar to the labeling...

Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results

March 15, 2011 4:35 am | by Bio-Medicine.Org | Comments

SEATTLE, March 15, 2011 /- Omeros Corporation (Nasdaq: OMER ), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth...

TOPICS:

Functional Technologies Awarded $2.5 Million from Government of Canada to Optimize Acrylamide-Preventing Yeast Technologies in Commercial Potato Processing

March 15, 2011 3:45 am | by The Associated Press | Comments

http://www.functionaltechcorp.com () —Functional Technologies Corp. (TSX VENTURE: FEB) (the "Company") is pleased to announce that its subsidiary, Phyterra Yeast Inc., has been awarded $2.5 million in non-dilutive funding from the Government of Canada's Atlantic Innovation Fund (AIF) under...

Argon Medical Devices Announces Exclusive License and Distribution Agreement for Optionâ„¢ Retrievable Inferior Vena Cava Filter

March 15, 2011 3:33 am | by Bio-Medicine.Org | Comments

ATHENS, Texas, March 15, 2011 /- Argon Medical Devices, Inc. announced today that it has entered into a definitive license agreement with Rex Medical, LP ("Rex Medical") for exclusive global rights to market and distribute the Option™ Retrievable Inferior Vena Cava Filter, an...

TOPICS:

BioDrain Medical, Inc. Retains CFSG1 as Its U.S. Investor Relations Firm

March 15, 2011 3:33 am | by Bio-Medicine.Org | Comments

MINNEAPOLIS, March 15, 2011 /- BioDrain Medical, Inc. (OTC Bulletin Board: BIOR ), producer of the FDA cleared Streamway™ System for automated surgical fluid disposal, announced today that it has retained Consulting for Strategic Growth 1 ("CFSG1") as its U.S. Investor Relations...

TOPICS:

OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals

March 15, 2011 12:34 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 15, 2011 /- OncoSec Medical Inc. (OTC Bulletin Board: ONCSD ), a developer of innovative and proprietary medical approaches to treat solid tumor cancers with unmet medical needs, announced today that it has signed an agreement with Inovio Pharmaceuticals, Inc. (NYSE Amex:...

TOPICS:

Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical

March 15, 2011 12:34 am | by Bio-Medicine.Org | Comments

BLUE BELL, Pa., March 15, 2011 /- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. (OTC Bulletin Board:...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading